Top Five C15:0 Science Themes of The Year

January 4, 2026

Welcome to Issue #6 of Science Says! Our weekly newsletter where you'll learn the latest healthy aging and C15:0 research news that our team of doctors, scientists, and experts are most excited about—without having to go search for it.

Eric and Steph
Co-Founders, Doctors, Nerds

What Dr. Stephanie Venn-Watson, our co-founder and author of *The Longevity Nutrient* and our PhD peer-reviewed scientific publications, is reading.

HEALTHY AGING

A Year of Revalidation

Last year was another big year of newly published, peer-reviewed science supporting C15:0's health benefits. With an average of about one new scientific paper relevant to C15:0's health benefits published per week throughout 2025 (for prior years' papers, including another study, proposing C15:0 as an essential fatty acid (Venn-Watson et al. 2020, Dronn et al. 2020, Ciosicki et al. 2024).

Bottom line: From nematodes to rats to dolphins to humans, C15:0 is emerging as an essential nutrient we all need to grow and thrive.

#2: Use of C15:0 To Reverse A Detailed Nutritional Deficiency Syndrome Was Revalidated. Check.

In November, Addis et al. published an independent study revalidating how C15:0 reverses multiple components of a previously described nutritional C15:0 deficiency syndrome. In this study, they showed in a third animal species that *C15:0 supplementation effectively lowered lipid peroxidation, proinflammatory cytokines, and harmful iron deposition; protected liver function and red blood cell integrity; and reversed biomarkers of hemolysis*. These findings aligned with the prior description of a nutritional C15:0 deficiency syndrome, named Cellular Fragility Syndrome, which involves weakened red blood cells, increased lipid peroxidation and ferroptosis (a new form of cell death that causes abnormal iron deposition), leading to impaired liver, immune, cardiometabolic, and cognitive function (Venn-Watson et al. 2021, Dronn et al. 2021).

Bottom line: There is increasing support that C15:0 reverses the entirety of a nutritional C15:0 deficiency syndrome, including ferroptosis, a newly discovered form of cell death that accelerates aging.

#3: Higher C15:0 Was Incrementally Associated With Better Long-Term Cardiometabolic Health. Again. And Again.

Hot off the presses, Schaefer et al. just published an extensive meta-analysis of 27 prospective cohort studies following over 100,000 people. This meta-analysis showed that there is a dose-response relationship between higher C15:0 and associated better long-term protected metabolic health. Specifically, *for every 0.1% increase in C15:0 levels, there was an associated 12% improvement in overall long-term metabolic health* (we'll cover this study more next week). Sun et al.'s meta-analysis reported similar incrementally improved outcomes in long-term studies. Both in September. On the cardiovascular health front, Aghaseyedi et al., Chen et al., and Huang et al. all published studies during 2025 that the higher one's C15:0 levels, the better the associated protected vascular and blood pressure health - for both the near-term and long-term.

Bottom line: Numerous robust prospective clinical studies, paired with C15:0's dose-response science, have demonstrated in experimental studies, increasingly support that the higher our C15:0 levels, the better the protected our long-term cardiometabolic health.

#4: C15:0 Is Emerging As Important To Early Development, Too.

In Yuan et al.'s 2025 study, they followed up 1,200 mother-child pairs over a period of six years and showed that the higher the C15:0 levels in mothers during pregnancy (and breastfeeding, as well as *the higher the C15:0 in mom's milk, the better the overall cognitive, behavioral, and language abilities in her child at ages 3 and 5-6 years old*. This matched the earlier mentioned study by Ruan et al. showing that C15:0 has a direct positive effect on the neurodevelopment in *C. elegans*. Further, Duan et al.'s study published in May showed that piglets, which are a common model for human infant nutritional studies, that C15:0 replacers supplemented with pure C15:0 had better daily growth, gut health, and mitochondrial function compared to piglets without milk replacers. These studies further support prior studies from George et al. and Li et al. showing that higher C15:0 from mom is associated with better human fetal and infant growth and development.

Bottom line: These studies support that C15:0 is not just associated with, but plays an active role, in whole body growth and cognitive development.

#5: C15:0 For Brain Health Is Getting Our Attention.

In April, we published the discovered role of C15:0 as a dose-dependent activator of PPARδ, a master regulator of NAD+ and FAAH. Molecules that inhibit these enzymes, especially as we get older, are considered neuroprotectants because *these activities support higher, healthier dopamine and endocannabinoid levels*. Together, dopamine and endocannabinoids promote healthy brain function, mood, and sleep. Which may help explain why prior studies from Shen et al. and Brydges et al. have associated higher C15:0 with better cognitive and mood health. These studies further support prior studies from George et al. and Li et al. showing that higher C15:0 from mom is associated with better human fetal and infant growth and development.

Bottom line: These studies support that C15:0 is not just associated with, but plays an active role, in whole body growth and cognitive development.

#5: C15:0 For Brain Health Is Getting Our Attention.

In April, we published the discovered role of C15:0 as a dose-dependent activator of PPARδ, a master regulator of NAD+ and FAAH. Molecules that inhibit these enzymes, especially as we get older, are considered neuroprotectants because *these activities support higher, healthier dopamine and endocannabinoid levels*. Together, dopamine and endocannabinoids promote healthy brain function, mood, and sleep. Which may help explain why prior studies from Shen et al. and Brydges et al. have associated higher C15:0 with better cognitive and mood health. These studies further support prior studies from George et al. and Li et al. showing that higher C15:0 from mom is associated with better human fetal and infant growth and development.

Bottom line: These studies support that C15:0 is not just associated with, but plays an active role, in whole body growth and cognitive development.

#5: C15:0 For Brain Health Is Getting Our Attention.

In April, we published the discovered role of C15:0 as a dose-dependent activator of PPARδ, a master regulator of NAD+ and FAAH. Molecules that inhibit these enzymes, especially as we get older, are considered neuroprotectants because *these activities support higher, healthier dopamine and endocannabinoid levels*. Together, dopamine and endocannabinoids promote healthy brain function, mood, and sleep. Which may help explain why prior studies from Shen et al. and Brydges et al. have associated higher C15:0 with better cognitive and mood health. These studies further support prior studies from George et al. and Li et al. showing that higher C15:0 from mom is associated with better human fetal and infant growth and development.

Bottom line: These studies support that C15:0 is not just associated with, but plays an active role, in whole body growth and cognitive development.

#5: C15:0 For Brain Health Is Getting Our Attention.

In April, we published the discovered role of C15:0 as a dose-dependent activator of PPARδ, a master regulator of NAD+ and FAAH. Molecules that inhibit these enzymes, especially as we get older, are considered neuroprotectants because *these activities support higher, healthier dopamine and endocannabinoid levels*. Together, dopamine and endocannabinoids promote healthy brain function, mood, and sleep. Which may help explain why prior studies from Shen et al. and Brydges et al. have associated higher C15:0 with better cognitive and mood health. These studies further support prior studies from George et al. and Li et al. showing that higher C15:0 from mom is associated with better human fetal and infant growth and development.

Bottom line: These studies support that C15:0 is not just associated with, but plays an active role, in whole body growth and cognitive development.

What a year! And to think - these are studies that are so new, they are not in our USA Today Bestseller Simon & Schuster book, *The Longevity Nutrient*, which covers 100- other peer-reviewed studies on C15:0.

Have a fantastic week, everyone! Here's to a healthy, science-enriched 2026.

Dive deeper into the science

READ THESE STUDIES AT
DISCOVERYNL.COM/RESOURCES

- Ciosicki, V. et al. Dietary pentadecanoic acid supplementation at weaning in essential fatty acid deficient rats. Prostaglandins Leukot Essent Fatty Acids (Short n-6 Pufas). J Nutritional Biochemistry 137-138514 (2025).
- Ruan, M. et al. Fine long-chain fatty acids trigger early postembryonic development in starved Caenorhabditis elegans by suppressing mTORC1. PLOS Biol 22:e3002841 (2024).
- Venn-Watson, S., Lumpkin, R., Dennis, E.A. Efficacy of dietary odd-chain saturated fatty acids (C15:0) against COVID-19 and partially bread associated health benefits in humans: could it be essential? Sci Rep 10:16444 (2020).
- Dornen, K. et al. Odd chain fatty acids and odd chain phospholipids are biomarkers and are essential for diet. J Am Chem Soc 98:813-824 (2021).
- Ciosicki, V. et al. New insights on pentadecanoic acid with special focus on its controversial essentiality: a mini-review. Nutrition 127:123-129 (2024).
- Aebis, M. et al. Pentadecanoic acid improves liver function by modulating gut microbiota, intestinal response, and ferroptosis pathways in rat. Nuwn Biotechnol Adv 83:108377 (2025). S1007-0974(25)00148-0 (2025).
- Venn-Watson et al. The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Pathology in Cellular Fragility Syndrome (Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome). Metabolites 14, 355 (2024).
- Dronn et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death (2012).
- Schaefer et al. Fatty acid biomarkers and protected health: a systematic and quantitative review of dose-response meta-analyses of prospective observational studies. Adv Nutr 17,100565 (2026).
- Sun et al. Erythrocyte odd chain fatty acids and cardiometabolic health: a dose-response meta-analysis. Eur J Prev Cardiol 2447507 (2025).
- Aghaseyedi et al. Impact of dairy intake on circulating fatty acids and associations with blood pressure: a Mendelian randomization trial. Nutr Metab Cardiovasc Dis In Press (2025).
- Chen et al. Associations between serum pentadecanoic acid (C15:0) and metabolomics and clinical traits and hypertension: a cross-sectional analysis of NHANES data. Lipids Health Dis 24, 219 (2025).
- Huang et al. Associations of erythrocyte membrane fatty acids with blood pressure in children. Clin Nutr 44, 30-36 (2025).
- Yuan, W.L. Associations between perinatal biomarkers of maternal dairy fat intake and child cognitive development: results from the EDEN mother-child cohort. Eur J Clin Nutrition 79:320-328 (2025).
- Ruan, M. et al. Free long-chain fatty acids trigger early postembryonic development in starved Caenorhabditis elegans by suppressing mTORC1. PLOS Biol e3002841 (2024).
- George, A.D. et al. The fatty acid species and quantity consumed by the breastfed infant are important for growth and development. Nutrients 13, 4164 (2021).
- Li et al. Early pregnancy maternal plasma phospholipid saturated fatty acids and fetal growth: findings from a multi-racial/ethnic birth cohort in the US. Nutrients 15, 3287 (2023).
- Venn-Watson, S.K., Jensen, E.D. Aging associated atypical beta oxidation and reversal by pentadecanoic acid: beyond healthy aging in bottlenose dolphins (Tursiops truncatus) and non-human primates. Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology 164, 551-558 (2013).
- Shen et al. The Associations between plasma fatty acid and cognitive function moderated by chronic inflammation. Diabetes, Metabolic Syndrome and Obesity 15, 1423-1436 (2022).
- Brydges, C.R. et al. Metabolomic and inflammatory signatures of symptoms dimensions in major depression. Brain Behav Immun 102, 42-52 (2022).

CLINICAL TRIALS WITH C15:0

- Stallings et al. (2016) J Clin Pharmacol The+ 51, 263-273.
- Moscarelleo et al. (2013). J Clin Pharmacol 53, 854-865.
- Robinson et al (2024) J Nutr 154, 2763-2771.
- Chooi et al. (2024) Am J Clin Nutr 119, 788-799.
- Salamanca-Sanabria et al. (2025) Front Nutr 12, in Press.
- Mirzi et al. (2021) Nutrients 13, 1145.
- Aghaseyedi et al. (2025) Nutr Metab, Cardiovasc Dis 35,104112.
- Kaneda et al. (2020) Med Cons New+Remed 60, 459-470.

An Amazon #1 Best Seller

"A groundbreaking, once-in-a-century discovery that changes how we think about the better."

Dr. Mark Hyman
The New York Times Bestseller

Order now

fattyᵀᴹ

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Unsubscribe
Update Profile
2907 Shelter Island Dr. Ste. 105-441 San Diego, CA 92106